NCT01806298View on ClinicalTrials.gov

An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)

PHASE4CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Adult Growth Hormone Deficiency
Interventions
DRUG

Saizen® solution for injection (referred as Saizen®)

Saizen® solution for injection will be administered subcutaneously daily for 39 weeks according to locally approved product labeling for the currently marketed formulation of Saizen®.

Trial Locations (19)

2010

Research site, Darlinghurst

3065

Research site, Fitzroy

3168

Research site, Clayton

5041

Research site, Adelaide

6009

Research site, Perth

13344

Research site, Berlin

17176

Research site, Stockholm

26122

Research site, Oldenburg

41345

Research site, Gothenburg

97080

Research site, Würzburg

Unknown

Research site, Birmingham

TS4 3BW

Research site, Cleveland

GU2 7XX

Research site, Guildford

L69 3PX

Research site, Liverpool

M20 4BX

Research site, Manchester

M6 8HD

Research site, Manchester

PE30 4ET

Research site, Norfolk

OX3 7LJ

Research site, Oxford

TR1 3LJ

Research site, Truro

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01806298 - An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) | Biotech Hunter | Biotech Hunter